KSI-501 in DME: The ongoing Phase 3 ALTO study is designed to explore differentiated efficacy and durability Primary endpoint Key secondary endpoint Mean change in BCVA from baseline to the average of Weeks 48 and 52 Proportion of subjects improving 2 steps on Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 Phase 3 ALTO Objective: Explore efficacy of bispecific IL-6 and VEGF inhibition + 6-month durability potential in DME Superiority 6-month durability potential 44